JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The association between proton-pump inhibitor use and recurrence of hepatocellular carcinoma after hepatectomy

  • 0Department of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Journal of Gastroenterology and Hepatology +

|

June 12, 2024

|

June 12, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Long-term use of proton-pump inhibitors (PPIs) may reduce the recurrence of hepatocellular carcinoma (HCC) after surgery. This study found that prolonged PPI use was linked to better recurrence-free survival in HCC patients, but not overall survival.

Area Of Science

  • Hepatobiliary Surgery
  • Gastroenterology
  • Oncology

Background

  • The link between long-term proton-pump inhibitor (PPI) use and various malignancies remains debated.
  • Hepatocellular carcinoma (HCC) recurrence after surgical resection is a significant clinical concern.

Purpose Of The Study

  • To investigate the association between PPI usage and the recurrence of HCC following curative hepatectomy.
  • To evaluate the impact of different durations of PPI use on recurrence-free survival (RFS) and overall survival (OS) in HCC patients.

Main Methods

  • Retrospective analysis of 6037 patients with HCC who underwent hepatectomy.
  • Patients categorized into non-users (<28 cDDD), short-term (28-89 cDDD), mid-term (90-179 cDDD), and long-term (≥180 cDDD) PPI users.
  • Recurrence-free survival (RFS) and overall survival (OS) analyzed using Kaplan-Meier and Cox proportional hazard models.

Main Results

  • PPI users (33.84%) showed improved median RFS compared to non-users (3.10 vs 2.73 years; aHR 0.57).
  • Only long-term PPI users (≥180 cDDD) demonstrated a significantly lower risk of HCC recurrence (adj-HR 0.50).
  • No significant difference in overall survival was observed between PPI users and non-users (4.23 vs 4.04 years).

Conclusions

  • Long-term PPI use (≥180 cDDD) is associated with a reduced risk of HCC recurrence after hepatectomy.
  • The protective effect on RFS was consistent across most subgroups, except for advanced tumor stages, non-cirrhosis, and chronic kidney disease.
  • Long-term PPIs do not appear to influence overall survival in this HCC patient cohort.

Keywords: